1. Search Result
Search Result
Results for "

blood+glucose

" in MedChemExpress (MCE) Product Catalog:

242

Inhibitors & Agonists

3

Biochemical Assay Reagents

11

Peptides

1

Inhibitory Antibodies

61

Natural
Products

9

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2149
    Concanavalin A
    5 Publications Verification

    Mitosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Concanavalin A can be coupled to agarose to form Concanavalin A (agarose) (HY-P2149A). Concanavalin A (ConA) is a selective, competitive binding agent that targets specific carbohydrate structures containing glucose and mannose; it acts as a mitogen and exhibits varying degrees of cytotoxicity, hepatotoxicity, and teratogenicity. Concanavalin A is also utilized for in vivo blood glucose monitoring in the context of diabetes .
    Concanavalin A
  • HY-14860
    1-Deoxynojirimycin
    5+ Cited Publications

    Duvoglustat

    Glycosidase PI3K Metabolic Disease
    1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin
  • HY-17638
    Mizagliflozin
    5 Publications Verification

    DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base

    SGLT Metabolic Disease
    Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
    Mizagliflozin
  • HY-W012241

    Endogenous Metabolite PROTAC Linkers Metabolic Disease
    Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
    Dodecanedioic acid
  • HY-P3479

    Insulin Receptor Metabolic Disease
    Insulin (swine) is an orally active insulin derived from pigs. Insulin (swine) when administered orally acts as an antigen to reduce the severity of pancreatic lymphocyte infiltration, but has no metabolic effect on blood glucose levels. Insulin (swine) increases glucose oxidation, stimulates lipogenesis, and lowers blood glucose levels. Insulin (swine) can be used in diabetes research .
    Insulin (swine)
  • HY-14860A

    Duvoglustat hydrochloride

    Glycosidase PI3K Bacterial Antibiotic Infection Metabolic Disease
    1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin hydrochloride
  • HY-W050031
    (S)-3-Hydroxybutanoic acid
    2 Publications Verification

    (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid

    Endogenous Metabolite Metabolic Disease
    (S)-3-Hydroxybutanoic acid is a metabolite and a disease marker of depression. 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.
    (S)-3-Hydroxybutanoic acid
  • HY-148189
    Aldometanib
    5+ Cited Publications

    LXY-05-029

    Fructose-1,6-bisphosphate aldolase AMPK Metabolic Disease
    Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .
    Aldometanib
  • HY-120565

    G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes .
    WB403
  • HY-B2099A
    Buformin hydrochloride
    3 Publications Verification

    1-Butylbiguanide hydrochloride

    AMPK Cancer
    Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
    Buformin hydrochloride
  • HY-Y0624

    Endogenous Metabolite Mitochondrial Metabolism Metabolic Disease
    4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .
    4-Pentenoic acid
  • HY-N2842

    Apoptosis Caspase Metabolic Disease Cancer
    α-Amyrin acetate is a pentacyclic triterpenoid compound with oral activity. α-Amyrin acetate can inhibit cancer cells proliferation and induce apoptosis. α-Amyrin acetate can reduce blood glucose level. α-Amyrin acetate can be used for the researches of cancer and metabolic disease, such as breast cancer and diabetes .
    α-Amyrin acetate
  • HY-W005629

    Environmental Pollutants Cannabinoid Receptor PDK-1 Metabolic Disease Cancer
    Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .
    Leelamine
  • HY-W010031

    Drug Metabolite Endogenous Metabolite Metabolic Disease
    1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.
    1-Methyluric acid
  • HY-N1503

    6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester

    Others Metabolic Disease
    Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .
    Methyl deacetylasperulosidate
  • HY-N3960

    PPAR Bacterial Infection Metabolic Disease
    Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .
    Glycyrin
  • HY-120160

    CP-86325

    PPAR Neurological Disease Metabolic Disease
    Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
    Darglitazone
  • HY-131334

    AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-N3015

    Others Metabolic Disease
    Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .
    Bruceine E
  • HY-116930

    Melatonin Receptor Metabolic Disease
    S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .
    S-20928
  • HY-103433

    Dipeptidyl Peptidase Metabolic Disease
    K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .
    K579
  • HY-163853

    GLUT Akt Metabolic Disease
    Antidiabetic agent 6 (Compound 19) is an antidiabetic Agent. Antidiabetic agent 6 stimulates GLUT4 translocation by activation of the PI3K/AKT-dependent signaling pathway. Antidiabetic agent 6 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats .
    Antidiabetic agent 6
  • HY-14860R

    Duvoglustat (Standard)

    Reference Standards Glycosidase PI3K Metabolic Disease
    1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin (Standard)
  • HY-148529

    (±)-DG5128 free base; DG5128 free base

    Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .
    Midaglizole
  • HY-B2099

    1-Butylbiguanide

    AMPK Metabolic Disease Cancer
    Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
    Buformin
  • HY-150560

    Glycosidase Metabolic Disease
    α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .
    α-Glucosidase-IN-11
  • HY-156277

    PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-122613

    SGLT Metabolic Disease
    YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .
    YM543 free base
  • HY-12611

    GW-869682X

    SGLT Metabolic Disease
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .
    Sergliflozin etabonate
  • HY-W709961

    1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate

    Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .
    5-OAHSA
  • HY-128642

    FAP Cancer
    FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .
    FAPI-2
  • HY-144287

    Glucokinase Sodium Channel Metabolic Disease
    Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .
    Glucokinase activator 3
  • HY-U00340

    PPAR Metabolic Disease
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-12614

    Glucokinase Metabolic Disease
    AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC50 of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .
    AMG-1694
  • HY-I0144

    Drug Intermediate Others
    Thiazolidine is a five-membered heterocyclic compound containing sulfur and nitrogen heteroatoms. Thiazolidine is an important intermediate in organic synthesis. Thiazolidine derivatives possess diverse bioactivities, such as anti-tumor, antibacterial and insecticidal activities, and the capacity to reduce blood glucose levels .
    Thiazolidine
  • HY-117172

    Phosphorylase Metabolic Disease
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .
    CP320626
  • HY-164809

    ROCK Metabolic Disease
    KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity .
    Desisopropyle-belumosudil
  • HY-W097570
    Sulfamonomethoxine sodium
    1 Publications Verification

    Antibiotic Bacterial Infection Neurological Disease
    Sulfamonomethoxine sodium is an orally active broad-spectrum synthetic sulfonamide antibiotic that inhibits dihydropteroate synthetase. Sulfamonomethoxine sodium increases blood glucose levels, induces anxiety-related activities and impairs spatial learning and memory. Sulfamonomethoxine sodium can be used for the research of anxiety, spatial memory impairment, colisepticemia, salmonellosis, and staphylococcus infection .
    Sulfamonomethoxine sodium
  • HY-174145

    GLUT Metabolic Disease
    GLUT4 activator 3 (Compound 13a) is an antidiabetic agent targeting GLUT4 translocation in skeletal muscle. GLUT4 activator 3 can promote the translocation of glucose transporter 4 (GLUT4) in skeletal muscle cells. GLUT4 activator 3 reduces blood glucose in STZ-induced diabetic rats .
    GLUT4 activator 3
  • HY-164425

    Phosphatase STAT Metabolic Disease
    ENT-03 is a centrally acting mammalian aminosterol. ENT-03 upregulates cFos activation, inhibits PTP1b and induces phosphorylation of STAT3. ENT-03 normalizes blood glucose, induces weight loss. ENT-03 can be used in the research of type 2 diabetes and obesity .
    ENT-03
  • HY-128642A

    FAP Cancer
    FAPI-2 TFA is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 TFA has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .
    FAPI-2 TFA
  • HY-14810

    AVE-2268

    SGLT Metabolic Disease
    Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
    Atigliflozin
  • HY-P10337

    GCGR GLP Receptor Metabolic Disease Endocrinology
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
    OXM-7
  • HY-119311

    PPAR Metabolic Disease
    Pioglitazone ketone is an active metabolite of the PPARγ agonist Pioglitazone (HY-13956). Formation of pioglitazone ketone occurs primarly through cytochrome P450 (CYP) isoform CYP2C8-mediated metabolism of pioglitazone. Pioglitazone ketone (100 mg/kg in the diet) reduces blood glucose levels in a KKAy mouse model of type 2 diabetes.
    Ketopioglitazone
  • HY-117446

    GPR119 Metabolic Disease
    AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .
    AS-1669058
  • HY-117446A

    GPR119 Metabolic Disease
    AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.
    AS-1669058 free base
  • HY-12219B

    Others Metabolic Disease
    MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.
    MSI-1701
  • HY-16149

    CPI-975

    Carnitine Palmitoyltransferase (CPT) Acyltransferase Metabolic Disease
    SDZ-CPI-975 is a novel, reversible, and selective CPT I inhibitor. SDZ-CPI-975 effectively inhibits fatty acid oxidation and lowers blood glucose levels .
    SDZ-CPI 975
  • HY-P991291

    Insulin Receptor Endocrinology
    XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
    XOMA 129
  • HY-101637

    JT 501

    PPAR Metabolic Disease
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
    Reglitazar

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: